long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay  by Auricchio, Angelo et al.
Heart Failure
Long-Term Clinical Effect of Hemodynamically
Optimized Cardiac Resynchronization Therapy in Patients
With Heart Failure and Ventricular Conduction Delay
Angelo Auricchio, MD, PHD,* Christoph Stellbrink, MD,‡ Stefan Sack, MD,¶ Michael Block, MD,
Ju¨rgen Vogt, MD,** Patricia Bakker, MD,†† Christof Huth, MD,† Friedrich Scho¨ndube, MD,§
Ulrich Wolfhard, MD,# Dirk Bo¨cker, MD, Olaf Krahnefeld, MD,** Hans Kirkels, MD, PHD,‡‡
for the Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group
Magdeburg, Aachen, Mu¨nster, Essen and Bad Oeynhausen, Germany and Utrecht, The Netherlands
OBJECTIVES We sought to compare the short- and long-term clinical effects of atrial synchronous
pre-excitation of one (univentricular) or both ventricles (biventricular), that provide cardiac
resynchronization therapy (CRT).
BACKGROUND In patients with heart failure (HF) who have a ventricular conduction delay, CRT improves
systolic hemodynamic function. The clinical benefit of CRT is still being investigated.
METHODS Forty-one patients were randomized to four weeks of first treatment with biventricular or
univentricular stimulation, followed by four weeks without treatment, and then four weeks of
a second treatment with the opposite stimulation. The best CRT stimulation was continued
for nine months. Cardiac resynchronization therapy was optimized by hemodynamic testing
at implantation. The primary end points were exercise capacity measures. Data were analyzed
by two-way repeated-measures analysis of variance.
RESULTS The left ventricle was selected for univentricular pacing in 36 patients. The clinical effects of
univentricular and biventricular CRT were not significantly different. The results of each
method were pooled to assess sequential treatment effects. Oxygen uptake during bicycle
exercise increased from 9.48 to 10.4 ml/kg/min at the anaerobic threshold (p  0.03) and
from 12.5 to 14.3 ml/kg/min at peak exercise (p  0.001) with the first treatment, and from
10.0 to 10.7 ml/kg/min at the anaerobic threshold (p 0.2) and from 13.4 to 15.2 ml/kg/min
at peak exercise (p  0.002) with the second treatment. The 6-min walk distance increased
from 342 m at baseline to 386 m after the first treatment (p  0.001) and to 416 m after the
second treatment (p  0.03). All improvements persisted after 12 months of therapy.
CONCLUSIONS Cardiac resynchronization therapy produces a long-term improvement in the clinical
symptoms of patients with HF who have a ventricular conduction delay. The differences
between optimized biventricular and univentricular therapy appear to be small for short-term
treatment. (J Am Coll Cardiol 2002;39:2026–33) © 2002 by the American College of
Cardiology Foundation
Both natural (1,2) and experimentally induced (3) ventric-
ular conduction delays generate uncoordinated ventricular
contractions that reduce the pumping effectiveness of the
heart (4), and they have been linked with a poor outcome in
heart failure (HF) (5–7). Electrophysiologic and hemody-
namic studies of patients with HF who have a predomi-
nately left ventricular (LV) conduction delay have shown
significant improvements in LV systolic function (8,9), with
decreased myocardial energy demand (10), when simulta-
neously pre-exciting the right ventricle (RV) and LV
(biventricular) or just the LV synchronized to sinus rhythm.
This biventricular or LV pre-excitation apparently resyn-
chronizes RV and LV contractions (11), as well as LV septal
and lateral wall contractions (12,13). Also, for patients with
a prolonged atrioventricular (AV) delay, atrial synchronous
pre-excitation improves AV timing (14,15). Collectively, we
refer to these methods as cardiac resynchronization therapy
(CRT).
Only the short-term effects of CRT, using nonoptimized
biventricular stimulation, have been tested in clinical studies
up to now (16–18). No randomized study has investigated
whether the hemodynamic benefit, that is similar with
biventricular and LV CRT (9), translates into a similar
clinical outcome. The multicenter, patient-blinded,
sequential-treatment, randomized, crossover Pacing Thera-
pies for Congestive Heart Failure (PATH-CHF) pilot
study was designed in 1995 to test the hypothesis that
hemodynamically optimized CRT would produce a long-
term improvement in the exercise tolerance and quality of
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life of patients with severe HF, sinus rhythm and a ventric-
ular conduction delay, who were receiving optimal, maxi-
mally tolerated pharmacologic therapy. The crossover of
CRT methods was used to verify the hypothesis that
LV-only stimulation, or RV-only stimulation, whichever is
hemodynamically superior, would not have clinical effects
significantly different from those of biventricular stimula-
tion, when the stimulation is individually optimized to
provide maximal initial hemodynamic improvement.
METHODS
Patients. Patients were eligible if they had New York
Heart Association (NYHA) functional class III or IV
symptoms for six months before enrollment, despite optimal
pharmacologic therapy, which may have included an
angiotensin-converting enzyme inhibitor, loop diuretic, va-
sodilator, nitrate, digitalis and beta-blocker, if tolerated. All
patients had been diagnosed by coronary angiography as
having dilated cardiomyopathy of any etiology, sinus
rhythm 55 beats/min, a QRS complex duration 120 ms
in at least two surface electrocardiographic (ECG) leads and
a PR interval 150 ms.
Exclusion criteria have been previously described (17).
Briefly, patients were excluded if they had primary operable
valvular heart disease (other than mitral or tricuspid regur-
gitation with clinical symptoms due to LV systolic HF), an
indication for conventional pacemaker or implantable
cardioverter-defibrillator or other noncardiac conditions
that could limit their exercise capacity and life expectancy.
The seven participating institutions’ review boards approved
the protocol, and all patients provided written, informed
consent.
Protocol. After the initial evaluation, the patients were
implanted with two dual-chamber pacemakers (Vigor or
Discovery, Guidant Corp., St. Paul, Minnesota)—one en-
docardially connected to the right atrium and RV at the
apex, and the other independently and endocardially con-
nected to the right atrium and epicardially to the LV
through a limited thoracotomy. At implantation, the pa-
tients were instrumented for acute hemodynamic testing, as
previously reported in a preliminary analysis of the first 27
patients (9). The goals of hemodynamic testing were to
select the optimal univentricular stimulation and to deter-
mine the best AV delay. The maximum rate of change in
LV pressure and aortic pulse pressure were used for opti-
mization (9). Pacemakers were programmed according to
results of hemodynamic testing, as previously reported (19).
An atrial synchronous tracking mode without atrial pacing
(VDD mode) was programmed with a lower rate limit of 40
beats/min. The randomization was designed to achieve a 1:1
ratio for univentricular and biventricular stimulation (Fig.
1). At implantation, the patients who were blinded to the
treatment sequence were randomized to four weeks of
univentricular or biventricular stimulation (first treatment
period), followed by four weeks of no treatment, and then
the therapy was started again with the opposite stimulation
for another four weeks (second treatment period). Clinical
measurements were made at pre-implantation (baseline)
and at the end of each period, or in case of early termination,
before the patient entered the next period.
At the end of the second treatment period, patients
continued to receive CRT. The attending physician selected
long-term therapy programming that provided the best
therapeutic effect, based on their judgment. Patients re-
turned for clinical follow-up and cardiopulmonary testing at
12 months after implantation.
Clinical measurements. The primary end points were
oxygen uptake at peak exercise, oxygen uptake at the
anaerobic threshold and the 6-min walk distance. The
secondary end points were changes in NYHA functional
class and quality of life. All clinical data pertinent to the
primary and secondary end points were independently
reviewed for protocol compliance, uniformity of measure-
ment procedures and final data analysis at the core centers,
whose investigators were blinded to the patients’ treatment.
The 6-min walk distance and quality-of-life tests were
administered by study nurses who had no knowledge of the
patients’ treatment. Cardiopulmonary exercise testing was
conducted on an upright bicycle ergometer with a 10-W/
min step protocol, starting with 2 min of unloaded cycling.
The ventilatory threshold was measured by the V-slope
method (20). The 6-min walk test was performed according
to Bittner (21). The cardiopulmonary and walk tests were
performed on different days. The self-administered Minne-
sota Living with Heart Failure questionnaire (22) was used
for scoring quality of life on a scale from 0 (best) to 105
(worst). The mean and minimal heart rates and standard
deviation of averaged normal R-to-R intervals (SDANN),
which is a measure of heart rate variability (23), were
obtained from custom-designed, digital 24-h ECG Holter
monitors worn by 15 randomly determined patients at the
end of each crossover period.
Statistics. The sample size was calculated at 53 patients,
based on primary end point changes and variability for 80%
power at a significance level of 0.05, as reported in the
PATH-CHF study design (19). Because of the emerging
availability of transvenous lead delivery systems, the Data
Abbreviations and Acronyms
ANOVA  analysis of variance
AV  atrioventricular
CRT  cardiac resynchronization therapy
ECG  electrocardiogram/electrocardiographic
HF  heart failure
LV  left ventricle/left ventricular
NYHA  New York Heart Association
PATH-CHF  Pacing Therapies in Congestive Heart
Failure study
RV  right ventricle or ventricular
SDANN  standard deviation of averaged normal
R-to-R intervals
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and Safety Monitoring Committee requested an indepen-
dent statistician to re-assess the sample size, based on data
from the first 27 patients. The Investigator Steering Com-
mittee decided to accept a new sample size of 42 to limit the
number of thoracotomies, with the understanding that it
might create an imbalance in the study groups.
The analysis of variance (ANOVA) model for acute
hemodynamic testing has been extensively described (9).
Two-way ANOVA with an additional co-variate to identify
the effects due to stimulation order was used to compare
univentricular and biventricular stimulation methods for
continuous clinical variables, and the Wilcoxon matched-
pairs test was used to compare methods for NYHA func-
tional classes. Contingent on the nonsignificance of the
stimulation method differences, repeated-measures
ANOVA with the Tukey-Kramer multiple comparisons
correction was used to evaluate period effects among the
baseline, first treatment, no treatment and second treatment
periods for continuous clinical variables, and the Wilcoxon
matched-pairs test was used to evaluate period effects for the
NYHA functional classes. Crossover data were analyzed
with the carry-forward principle for missing data. The
12-month data were analyzed by the paired t test and
compared with the pre-implantation measurements. Data in
the text are presented as sample mean value  SD.
RESULTS
Study group. Forty-two patients were enrolled in the
study, and 41 patients received implants (Fig. 1). Their
baseline characteristics are listed in Table 1. Most patients
(71%) had a QRS duration 150 ms. All patients were in
stable chronic HF under maximally tolerated pharmacologic
therapy at implantation, including diuretics and anticoagu-
Figure 1. Flow chart of the Pacing Therapies in Congestive Heart Failure study, which was conducted between August 1995 and October 1998. CRT 
cardiac resynchronization therapy; NYHA  New York Heart Association; SCD  sudden cardiac death; VT  ventricular tachycardia.
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lants in all patients (Table 1). Implanted patients in each
randomization group had similar baseline characteristics.
Implantation. The thoracotomy was well tolerated by all
but one patient, who experienced sustained wound pain
during preliminary treatment. Implantation of a LV lead
was successful in all 41 patients in whom it was attempted.
The LV lead was located on the apical to mid-lateral wall in
two-thirds of the patients and on the anterior wall in
one-third of the patients. In three patients, exit block
developed due to increased stimulation thresholds. Treat-
able atrial fibrillation occurred in four patients, generally 48
to 72 h after implantation, and they required direct current
cardioversion followed, in some cases, by anti-arrhythmic
medication.
Initial hemodynamic response to ventricular stimulation.
The hemodynamic data collected in all 40 patients in whom
hemodynamic recording was possible, did not differ from
the data previously reported for 27 patients (9). Atrial
synchronous ventricular stimulation increased LV systolic
function, but the magnitude of the increase depended on the
site stimulated and the AV delay (Fig. 2). The systolic and
diastolic responses to optimized univentricular and biven-
tricular stimulation are compared in Table 2. These opti-
mized responses were clinically very similar, within 2% for
systolic measures and within 3% for diastolic measures.
Based on these hemodynamic test results, the optimal
univentricular stimulation was selected to be the LV in 36
patients and the RV in 4 patients.
Comparison of univentricular and biventricular stimula-
tion. The difference between the numbers of patients in the
univentricular and biventricular groups was the result of
early study termination (see Methods). The effect of the
stimulation order during the crossover period was not
significant for any clinical measure (p  0.504). As shown
in Table 3, which pools the treatment periods for each type
of stimulation, there were no significant differences between
the univentricular and biventricular stimulation effects on
any end point. During the crossover period, there were no
systematic changes in the drug regimen or dosage, except
that the use of diuretics was reduced.
Sequential treatment effects. Measurements with both
types of stimulation were pooled to analyze the effects of
CRT compared with no treatment. The first and second
treatment effects combined for all patients are shown in
Table 4. After a four-week first treatment period adminis-
tered immediately after implantation, all end points signif-
icantly improved from baseline. In contrast, at the end of
the following no treatment period, the patients’ NYHA
functional class worsened compared with the first treatment
period, and the bicycle exercise capacity declined to near
baseline levels, whereas the 6-min walk distance and
quality-of-life score improvements were unchanged. After
Table 1. Baseline Characteristics of the PATH-CHF Study Group
Characteristic
Randomized to
Biventricular
Stimulation
(n  24)
Randomized to
Univentricular
Stimulation
(n  17)
All Enrolled
Patients*
(n  42)
Age (yrs) 59  7 60  5 60  7
Gender (men/women) 11/13 10/7 21/21
Cause of heart failure
Coronary artery disease 10 (42%) 1 (6%) 12 (29%)
Nonischemic dilated cardiomyopathy 14 (58%) 16 (94%) 30 (71%)
New York Heart Association Functional class (III/IV) 21/3 14/3 36/6
Electrocardiographic measurements
Rest heart rate (beats/min) 77  16 80  13 78  15
PR interval (ms) 190  34 207  30 196  33
QRS duration (ms) 174  30 178  34 175  32
Left bundle branch block 21 (87%) 17 (100%) 39 (93%)
Right bundle branch block 3 (13%) 0 3 (7%)
Echocardiographic measurements†
LVEF (%) 21  6 20  7 21  7
LVEDD (mm) 71  10 75  13 73  11
LVESD (mm) 62  9 68  14 64  12
Medication
ACE inhibitor (captopril) or Digitalis (digoxin)‡ 23 (96%) 17 (100%) 40 (95%)
Vasodilators or nitrates 17 (71%) 12 (71%) 29 (69%)
Beta-blockers (metoprolol)§ 17 (71%) 11 (65%) 28 (67%)
Amiodarone 7 (29%) 6 (35%) 13 (30%)
*One enrolled patient was not randomized. †Patient with aortic stenosis excluded. ‡Dosage 98  50 mg/day. §Dosage 40  20
mg/day. Dosage 246  88 mg/day. Data are presented as the mean value  SD or number (%) of patients.
ACE  angiotensin-converting enzyme; LVEF  left ventricular ejection fraction; LVEDD  left ventricular end-diastolic
diameter; LVESD  left ventricular end-systolic diameter.
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the second treatment period, both oxygen uptake at peak
exercise and the 6-min walk distance significantly increased
compared with the no treatment period (Table 4). Oxygen
uptake at the anaerobic threshold and quality-of-life scores
increased, but the effects were not significant. The patients’
NYHA functional class was significantly improved, with
63% of the patients improving to class I or II in the second
treatment period.
Heart rate changes. Compared with the no treatment
period, the second treatment resulted in significant de-
creases in the mean heart rate (from 76.9  11.9 beats/min
to 73.4  11.8 beats/min, p  0.01) and minimal heart rate
(from 62.7 13.5 beats/min to 57.4 12.6 beats/min, p
Figure 2. Comparison of hemodynamic responses to stimulation at different sites and atrioventricular (AV) delays, shown as the mean (SEM) percent
changes from baseline in the 40 patients in whom hemodynamic recording was possible. The top plots represent changes in systolic function and bottom
plots represent changes in diastolic function. BV biventricular stimulation; LV left univentricular stimulation; LVEDP left ventricular end-diastolic
pressure; max dP/dt  maximum rate of change in left ventricular pressure; min dP/dt  minimum rate of change in left ventricular pressure; RV  right
univentricular stimulation. Legend symbols indicate statistical differences between stimulation sites over all AV delays (p  0.001). †LV  RV and BV 
RV; ‡LV  BV and RV  BV; §BV  LV.
Table 2. Comparison of Initial Hemodynamic Responses to
Optimized Univentricular and Biventricular Stimulation
(Percentage Change from Baseline)
Parameter
Univentricular
Stimulation*
Biventricular
Stimulation
p
Value†
Best AV delay (ms) 112  36 112  33 1
LVESP (%) 4.3  5.9 4.3  6.0 0.684
LVEDP (%) 0.67  14.5 3.7  16.0 0.001
Aortic pulse pressure (%) 11.2  17.9 10.5  17.9 0.324
dP/dtmax (%) 18.4  16.6 17.0  15.8 0.001
dP/dtmin (%) 1.3  8.6 1.8  9.6 0.258
*Left ventricular stimulation in 36 patients and right ventricular stimulation in 4
patients. †All p values were derived from paired comparisons with the Tukey-Kramer
multiple comparisons correction following analysis of variance. Data are presented as
the mean value  SD.
AV  atrioventricular; dP/dtmax  maximum rate of change in left ventricular
pressure; dP/dtmin  minimum rate of change in left ventricular pressure; LVEDP 
left ventricular end-diastolic pressure; LVESP left ventricular end-systolic pressure.
Table 3. Biventricular Versus Univentricular Stimulation
Clinical Effects
Clinical Measure
Biventricular
Treatment
Univentricular
Treatment*
p
Value†
Oxygen uptake at peak exercise
(ml/kg/min)
14.91  0.66 14.58  0.77 0.324
Oxygen uptake at anaerobic
threshold (ml/kg/min)
10.70  0.47 10.39  0.51 0.290
6-min walk distance (m) 402  16 401  16 0.345
Quality-of-life score 25.2  3.3 28.1  3.5 0.069
NYHA functional class 0.360
IV 2 (5%) 3 (7%)
III 17 (41%) 14 (34%)
II 16 (39%) 15 (37%)
I 6 (15%) 9 (22%)
*Left ventricular stimulation in 36 patients and right ventricular stimulation in 4
patients. †All p values were derived from the F test for treatment method effects
following analysis of variance, except for NYHA functional class, which was derived
from the Wilcoxon matched-pairs test. Data are presented as the mean value  SEM
or number (%) of subjects.
NYHA  New York Heart Association.
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0.003), which were associated with significant increases in
heart rate variability (SDANN from 90.2  28.6 ms to
117  35.0 ms, p  0.001).
Safety. Seven patients did not complete the crossover study
(Fig. 1). The Data and Safety Monitoring Committee
excluded one patient whose documented aortic stenosis was
revealed at hemodynamic testing to be unacceptable for
implantation. During the first treatment period, two pa-
tients died suddenly and one developed ventricular tachy-
cardia. During the no treatment period, two patients refused
to have the device switched off and voluntarily withdrew.
Despite marked improvement in functional capacity, one
patient elected for heart transplantation because of organ
availability. In addition, one patient developed marked
bradycardia requiring continuous atrial pacing at the end of
the second treatment period.
One-year follow-up. At the end of the crossover phase,
the attending physicians chose not to reprogram the CRT in
29 patients; they reprogrammed it from biventricular to
univentricular stimulation in 2 patients and from univen-
tricular to biventricular stimulation in 4 patients. At the end
of 12 months after implantation, 29 patients (12 with
biventricular, 13 with LV and 4 with RV) returned for
follow-up testing. The magnitude of improvement at 12
months was similar to that observed at 3 months after
implantation (Table 5). In the one year prior to implanta-
tion, 22 patients (76%) were hospitalized for HF with an
average stay of 18.5  16.7 days, whereas in the one year
following implantation, 9 patients (31%) were hospitalized
for HF with an average stay of 4.5  9.3 days (p  0.001,
paired t test).
DISCUSSION
This is the first randomized study to show that different
resynchronization methods provide similar short- and long-
term clinical improvement when each method is individu-
ally optimized to provide maximal initial hemodynamic
benefit in patients with severe HF associated with a ven-
tricular conduction delay.
Cardiac resynchronization therapy improves exercise ca-
pacity and quality of life. Resynchronization therapy im-
proved the patients’ exercise capacity, NYHA functional
class and quality of life after one month of treatment, as
compared with baseline, and the improvements were repeat-
able after a second treatment period following one month
when therapy was suspended. After one year, on average,
the maximal exercise capacity had increased from 12.6 to
15.6 ml/kg/min, and 6-min walk performance increased
from 357 to 466 m. Differences of this magnitude might
improve the HF prognosis (24,25). Furthermore, com-
plaints scored by the quality-of-life questionnaire were cut
Table 4. Treatment Period Clinical Effects
Clinical Measure
Before
Implantation
First
Treatment
p
Value*
No
Treatment
Second
Treatment
p
Value*
Oxygen uptake at peak exercise (ml/kg/min) 12.50  0.56 14.34  0.63 0.001 13.37  0.67 15.15  0.80 0.002
Oxygen uptake at anaerobic threshold (ml/kg/min) 9.48  0.41 10.42  0.43 0.026 10.00  0.45 10.67  0.55 0.198
6-min walk distance (m) 342  17 386  17 0.001 394  17 416  15 0.028
Quality-of-life score 48.8  3.4 29.5  3.4 0.001 29.8  3.6 23.8  3.2 0.062
NYHA functional class 0.001 0.001
IV 6 (15%) 3 (7%) 5 (12%) 2 (5%)
III 35 (85%) 18 (44%) 22 (54%) 13 (32%)
II 0 14 (34%) 11 (27%) 17 (41%)
I 0 6 (15%) 3 (7%) 9 (22%)
*All p values were derived from paired comparisons with the Tukey-Kramer multiple comparisons correction following analysis of variance, except for NYHA functional class,
which was derived from the Wilcoxon matched-pairs test. Data are presented as the mean value  SEM or number (%) of subjects.
NYHA  New York Heart Association.
Table 5. Clinical Changes After 12 Months of Long-Term Treatment
Clinical Measure n
Before Implantation
(Baseline)
12 Months
of Treatment
p
Value*
Oxygen uptake at peak exercise
(ml/kg/min)
22 12.57  0.63 15.63  0.86 0.001
Oxygen uptake at anaerobic threshold
(ml/kg/min)
21 9.93  0.46 11.45  0.59 0.037
6-min walk distance (m) 25 357  20 446  15 0.001
Quality-of-life score 28 48.6  4.3 20.0  4.1 0.001
NYHA functional class 29 0.001
IV 4 (14%) 0
III 25 (86%) 8 (28%)
II 0 11 (38%)
I 0 10 (34%)
*All p values were derived from the paired t test, except for NYHA functional class, which was derived from the Wilcoxon
matched-pairs test. Data are presented as the mean value  SEM or number (%) of subjects.
NYHA  New York Heart Association.
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in half, and two-thirds of the patients improved to NYHA
functional class I or II. Because patients were already on
maximally tolerated, optimal pharmacologic therapy, in-
cluding angiotensin-converting enzyme inhibitors and beta-
blockers, these improvements represent a significant addi-
tional clinical benefit due to CRT.
Short- and long-term effects of CRT. Some of the
clinical improvement in the first treatment period may be
partially attributed to placebo effects. However, it is unlikely
that the significant incremental improvements in the second
treatment period can be attributed to a placebo effect,
because clinical measures decreased to baseline levels or did
not improve in the preceding patient-blinded, no treatment
period. Notably, increases in peak oxygen uptake were as
large with the second treatment as they were with the first
treatment. It is also noteworthy that a persistent reduction
in sympathetic tone occurred, as suggested by our evidence
that the mean and minimal 24-h heart rates decreased,
while heart rate variability increased, between the no treat-
ment and second treatment periods. The rapidity with
which CRT creates persistent changes is further suggested
by the finding that clinical improvements were sustained but
did not substantially increase from 3 to 12 months of
continuous CRT.
Univentricular and biventricular CRT provide similar
hemodynamic and clinical outcomes. Consistent with our
hypothesis, the clinical differences between hemodynami-
cally optimized biventricular and univentricular (predomi-
nantly LV) resynchronization methods were not significant,
although our ability to differentiate was limited by a small
sample size. Individual patients may benefit more with one
than with the other resynchronization method, and differ-
ences between methods may become evident by longer
follow-up. However, if this short-term similarity persists
with long-term follow-up, a CRT system with only LV
stimulation might be clinically useful. One possible inter-
pretation of the similarity between the biventricular and LV
treatments is that clinical improvement with CRT might
depend on the magnitude of hemodynamic improvement
due to CRT, which was similar for the optimized biven-
tricular and LV methods.
Study limitations. Cardiac resynchronization therapy ap-
pears promising in terms of improving a patient’s clinical
symptoms, although the impact on mortality is unknown.
Two patients had a sudden cardiac death, and one devel-
oped sustained ventricular tachycardia during the crossover
period, consistent with the expected incidence of spontane-
ous ventricular tachyarrhythmias in this population (26).
Also, two patients refused to continue the protocol in the
four-week no treatment period, because they could not
tolerate withdrawal of resynchronization therapy. Dropouts
could have biased the results, because of the sequential
crossover design. However, there were no significant differ-
ences between dropouts and other patients with respect to
any parameter at baseline. Furthermore, we used the con-
servative carry-forward method for the missing data, which
tends to reduce the actual differences between treatment
periods.
Hemodynamic and clinical improvements were demon-
strated only in patients in NYHA functional class III or IV,
with normal sinus rhythm and with a ventricular conduction
disorder, primarily left bundle branch block. Results with
other HF groups may differ. Cardiac resynchronization
therapy remains technically challenging, and implantable
devices expose patients to clinical risks, including device-
related symptoms, device failure and surgical complications.
Rapid technologic advances in device and lead design and
implantation techniques are simplifying the implantation
procedure and minimizing the risks (27).
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